PPARα and PPARγ regulate the nucleoside transporter hENT1

Biochemical and Biophysical Research Communications

Volumn 419, Issue 2, 2012, Pages 405-411

  Montero, Trinidad D ^a   Racordon, Dusan ^a   Bravo, Loreto ^a   Owen, Gareth I ^a   Bronfman, Miguel L ^a   Leisewitz, Andrea V ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Chemotherapeutic drugs; Equilibrative nucleoside transporter; PPAR

Indexed keywords

EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; LUCIFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIRINIXIC ACID;

ARTICLE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

CELL LINE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GENE EXPRESSION REGULATION; HUMANS; PPAR ALPHA; PPAR GAMMA; PROMOTER REGIONS, GENETIC; PYRIMIDINES; TRANSFECTION; UP-REGULATION;

EID: 84857998106     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.02.035     Document Type: Article

References (30)

1. Zhang J., Visser F., King K.M., Baldwin S.A., Young J.D., Cass C.E. The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer Metastasis Rev. 2007, 26:85-110.
2. Baldwin S.A., Beal P.R., Yao S.Y., King A.E., Cass C.E., Young J.D. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch. 2004, 447:735-743.
3. Yao S.Y., Ng A.M., Cass C.E., Baldwin S.A., Young J.D. Nucleobase transport by human equilibrative nucleoside transporter 1 (hENT1). J. Biol. Chem. 2011, 286:32552-32562.
4. Gati W.P., Paterson A.R., Belch A.R., Chlumecky V., Larratt L.M., Mant M.J., Turner A.R. Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to cytarabine (araC). Leuk. Lymphoma 1998, 32:45-54.
5. Galmarini C.M., Thomas X., Calvo F., Rousselot P., Rabilloud M., El Jaffari A., Cros E., Dumontet C. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br. J. Haematol. 2002, 117:860-868.
6. Achiwa H., Oguri T., Sato S., Maeda H., Niimi T., Ueda R. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci. 2004, 95:753-757.
7. Giovannetti E., Del Tacca M., Mey V., Funel N., Nannizzi S., Ricci S., Orlandini C., Boggi U., Campani D., Del Chiaro M., Iannopollo M., Bevilacqua G., Mosca F., Danesi R. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 2006, 66:3928-3935.
8. Marechal R., Mackey J.R., Lai R., Demetter P., Peeters M., Polus M., Cass C.E., Young J., Salmon I., Deviere J., Van Laethem J.L. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin. Cancer Res. 2009, 15:2913-2919.
9. Eltzschig H.K., Abdulla P., Hoffman E., Hamilton K.E., Daniels D., Schonfeld C., Loffler M., Reyes G., Duszenko M., Karhausen J., Robinson A., Westerman K.A., Coe I.R., Colgan S.P. HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. J Exp Med 2005, 202:1493-1505.
10. Petrovic V., Teng S., Piquette-Miller M. Regulation of drug transporters: during infection and inflammation. Mol. Interv. 2007, 7:99-111.
11. Soler C., Felipe A., Casado F.J., Celada A., Pastor-Anglada M. Nitric oxide regulates nucleoside transport in activated B lymphocytes. J. Leukoc. Biol. 2000, 67:345-349.
12. Braissant O., Foufelle F., Scotto C., Dauca M., Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996, 137:354-366.
13. Barbier O., Torra I.P., Duguay Y., Blanquart C., Fruchart J.C., Glineur C., Staels B. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2002, 22:717-726.
14. Fajas L., Debril M.B., Auwerx J. PPAR gamma: an essential role in metabolic control. Nutr. Metab. Cardiovasc. Dis. 2001, 11:64-69.
15. Schoonjans K., Staels B., Auwerx J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim. Biophys. Acta 1996, 1302:93-109.
16. Desvergne B., Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 1999, 20:649-688.
17. Rosen E.D., Sarraf P., Troy A.E., Bradwin G., Moore K., Milstone D.S., Spiegelman B.M., Mortensen R.M. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell 1999, 4:611-617.
18. Dulak J., Jozkowicz A. Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr. Cancer Drug Targets 2005, 5:579-594.
19. Michalik L., Desvergne B., Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat. Rev. Cancer 2004, 4:61-70.
20. Konieczna A., Lichnovka R., Erdosova B., Ehrmann J. The Role of PPARs in MDR - a lesson from embryonic development. Neoplasma 2009, 56:279-283.
21. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987, 162:156-159.
22. A.V. Leisewitz, E.I. Zimmerman, M. Huang, S.Z. Jones, J. Yang, L.M. Graves, Regulation of ENT1 expression and ENT1-dependent nucleoside transport by c-Jun N-terminal kinase. Biochem. Biophys. Res. Commun. 404 370-375.
23. Wei S., Yang J., Lee S.L., Kulp S.K., Chen C.S. PPARgamma-independent antitumor effects of thiazolidinediones. Cancer Lett. 2009, 276:119-124.
24. Leung G.P., Man R.Y., Tse C.M. Effect of thiazolidinediones on equilibrative nucleoside transporter-1 in human aortic smooth muscle cells. Biochem. Pharmacol. 2005, 70:355-362.
25. Vignati S., Albertini V., Rinaldi A., Kwee I., Riva C., Oldrini R., Capella C., Bertoni F., Carbone G.M., Catapano C.V. Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells. Neoplasia 2006, 8:851-861.
26. Cantini G., Lombardi A., Borgogni E., Francalanci M., Ceni E., Degl'Innocenti S., Gelmini S., Poli G., Galli A., Serio M., Forti G., Luconi M. Peroxisome-proliferator-activated receptor gamma (PPARgamma) is required for modulating endothelial inflammatory response through a nongenomic mechanism. Eur. J. Cell Biol. 2010, 89:645-653.
27. Choi J.H., Banks A.S., Estall J.L., Kajimura S., Bostrom P., Laznik D., Ruas J.L., Chalmers M.J., Kamenecka T.M., Bluher M., Griffin P.R., Spiegelman B.M. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 2010, 466:451-456.
28. Luconi M., Cantini G., Serio M. Peroxisome proliferator-activated receptor gamma (PPARgamma): is the genomic activity the only answer?. Steroids 2010, 75:585-594.
29. Tan N.S., Michalik L., Desvergne B., Wahli W. Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes. J. Steroid Biochem. Mol. Biol. 2005, 93:99-105.
30. Soler C., Valdes R., Garcia-Manteiga J., Xaus J., Comalada M., Casado F.J., Modolell M., Nicholson B., MacLeod C., Felipe A., Celada A., Pastor-Anglada M. Lipopolysaccharide-induced apoptosis of macrophages determines the up-regulation of concentrative nucleoside transporters Cnt1 and Cnt2 through tumor necrosis factor-alpha-dependent and -independent mechanisms. J. Biol. Chem. 2001, 276:30043-30049.